Wujcik D, Downs S
Crit Care Nurs Clin North Am. 1992 Mar;4(1):149-66.
BMT is an effective treatment for certain malignant and nonmalignant conditions. The source of the marrow is autologous or allogeneic. An allogeneic donor can be an HLA-matched related or unrelated donor. The patient undergoes intense chemoradiotherapy to remove remaining malignant cells and obliterate the immune system, thus allowing growth of the new bone marrow cells. Complications of conditioning therapy include pancytopenia and distinct organ toxicities. Astute nursing care is critical in managing the care of BMT patients. Assessment and numerous, interrelated interventions are required. Late complications of BMT relate to the conditioning therapy and to the transplant itself. As BMT becomes more readily available as a treatment, economic issues related to the cost of care and the allocation of resources challenge health care providers.
骨髓移植是治疗某些恶性和非恶性疾病的有效方法。骨髓来源为自体或异体。异体供者可以是人类白细胞抗原（HLA）匹配的亲属或非亲属供者。患者接受强化放化疗以清除残留的恶性细胞并破坏免疫系统，从而使新的骨髓细胞得以生长。预处理治疗的并发症包括全血细胞减少和明显的器官毒性。精心的护理对骨髓移植患者的护理至关重要。需要进行评估和众多相互关联的干预措施。骨髓移植的晚期并发症与预处理治疗及移植本身有关。随着骨髓移植作为一种治疗方法越来越容易获得，与护理成本和资源分配相关的经济问题对医疗保健提供者构成了挑战。
